Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Cytokine Release Syndrome × talquetamab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 14 Recurrence 2 Neoplasm, Residual 1 Hematologic Neoplasms 1 Cytokine Release Syndrome 1

Interventions

siltuximab 3 tocilizumab 1 talquetamab 1 obinutuzumab 1 glofitamab 1 axicabtagene ciloleucel 1 Oxaliplatin 1 Interleukin 1 Receptor Antagonist Protein 1 Gemcitabine 1 Gelsolin 1 Dexamethasone 1 Calcium Dobesilate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05972135 2026-02-23

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

SCRI Development Innovations, LLC

Phase 2 Recruiting

Cytokine Release Syndrome, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡